Analysts Set PDS Biotechnology Co. (NASDAQ:PDSB) Target Price at $14.25

PDS Biotechnology Co. (NASDAQ:PDSB) has received a consensus recommendation of “Buy” from the five brokerages that are currently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $14.25.

PDSB has been the topic of several research analyst reports. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. HC Wainwright reaffirmed a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Wednesday, October 2nd.

PDS Biotechnology Trading Up 3.3 %

PDS Biotechnology stock opened at $3.42 on Wednesday. The firm has a 50 day simple moving average of $3.24 and a 200-day simple moving average of $3.29. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The stock has a market capitalization of $125.44 million, a PE ratio of -2.51 and a beta of 1.90. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last released its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter in the previous year, the company posted ($0.37) earnings per share. As a group, equities research analysts expect that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in PDSB. Kathleen S. Wright Associates Inc. purchased a new stake in shares of PDS Biotechnology in the first quarter worth approximately $28,000. Tempus Wealth Planning LLC purchased a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $55,000. Ground Swell Capital LLC purchased a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $67,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $115,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology during the second quarter valued at approximately $120,000. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.